AgomAb Therapeutics NV American Depositary Shares
Yahoo Finance • last month
AtriCure, Inc. (ATRC) Beat Earnings Estimates. Here’s What Could Drive ATRC Stock Next
AtriCure, Inc. (NASDAQ:ATRC) has been delivering revenue growth and improved profitability, but the bigger question for investors is whether the latest results had any underlying catalysts strong enough to support the long-term growth pote... Full story
Yahoo Finance • 4 months ago
Agomab to Participate in Upcoming Conferences
Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the follow... Full story
- JPM
Mentioned:
Yahoo Finance • 4 months ago
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- Positive Interactions with U.S. Food an... Full story
Yahoo Finance • 5 months ago
AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447
AgomAb Therapeutics NV (NASDAQ:AGMB) is one of the 7 Best Strong Buy European Stocks to Invest In. On March 26, 2026, AgomAb Therapeutics NV (NASDAQ:AGMB) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,577,... Full story
Yahoo Finance • 5 months ago
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U... Full story
Yahoo Finance • 7 months ago
Agomab indicated to open at $15.50, IPO priced at $16
Agomab (AGMB) priced 12.5M shares at $16.00, inside the $15.00-$17.00 target range. JPMorgan, Morgan Stanley, Leerink and Kempen are acting as joint book running managers for the offering. Agomab is a clinical-stage biopharmaceutical compa... Full story